These biochips allow detailed dissection of disease processes at the cellular level where shear stress or continuous flow parameters are known to affect physiologic events. This innovation embodies the vista of microfluidics and nanotechnology furnishing the benefits of reduced sample and reagent volume (microlitre range), speedy assay time combined with the potential for automation and parallel processing.

Cellix gratefully acknowledge the support of Enterprise Ireland and their Commercialisation Funding Programme.